Nandrolone Phenylpropionate
Fast-acting nandrolone variant with 2.7-day half-life for precise pharmacokinetic control.
Nandrolone Phenylpropionate
Nandrolone Phenylpropionate is a sterile oil-based injectable preparation of nandrolone esterified with phenylpropionic acid, presented at 100 milligrams per millilitre in a 10 mL multiple dose vial. It delivers the pharmacological profile of nandrolone with a considerably shorter release phase than the decanoate ester.
Structural Profile
The active moiety is nandrolone, 19-nortestosterone, esterified at the 17-beta hydroxyl with phenylpropionic acid. The molecular formula is C27H34O3 with a molar mass of 406.56 g/mol, registered under CAS number 62-90-8. Absence of the carbon 19 methyl group is responsible for the elevated anabolic-to-androgenic ratio characteristic of the nandrolone series.
Esterification and Release
The phenylpropionate ester carries an aromatic ring and is appreciably less lipophilic than decanoate. Partition from the intramuscular depot is therefore faster, giving an earlier onset, a shorter duration of action and more rapid clearance once administration is discontinued. It is selected where finer control over serum levels is preferred to prolonged depot release.
Pharmacokinetic Profile
The elimination half-life is approximately 2.7 days. Serum concentrations peak within 24 to 48 hours and decline over the following days, so a shorter injection interval is required than with the decanoate ester. The urinary detection window for nandrolone metabolites extends to approximately 12 months, since detection is governed by the metabolites of the parent compound rather than by the ester.
Mechanism of Action
Nandrolone binds the cytoplasmic androgen receptor with high affinity and the activated complex regulates transcription at androgen response elements, promoting structural protein synthesis and nitrogen retention in skeletal muscle. Reduction by 5-alpha reductase yields dihydronandrolone, a metabolite of reduced androgenic activity, and aromatisation proceeds at a substantially lower rate than for testosterone.
Manufacturing and Sterility
Each production lot is released against the complete pharmaceutical testing protocol: HPLC identity confirmation and purity analysis with a specification of not less than 98 percent, verification of concentration against label claim within 5 percent, sterility testing in accordance with USP <71>, bacterial endotoxin quantification by LAL assay below 0.25 EU/mL, and particulate matter inspection in accordance with USP <788>. A Certificate of Analysis is issued for every lot.
Quality Assurance
Every batch of Nandrolone Phenylpropionate produced by Biomedica undergoes the complete pharmaceutical release testing protocol before distribution. This includes HPLC compound identity confirmation and purity analysis (specification: ≥98%), concentration verification (specification: ±5% of label claim), sterility testing per USP <71>, bacterial endotoxin quantification by LAL assay (specification: <0.25 EU/mL), and particulate matter inspection per USP <788>. A Certificate of Analysis is issued for every production lot.
Authentication
Each unit of Nandrolone Phenylpropionate carries a unique authentication code on its outer packaging. This code can be verified instantly on our Authentication page to confirm the product is genuine Biomedica stock.